← All trials
NCT06916793
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Dec 19, 2026
- Completion date
- Sep 17, 2027
- First posted
- Apr 8, 2025
- Last posted
- Apr 8, 2025
- Enrollment
- 288
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Seoul National UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.